The GOG 240 trial established that adding bevacizumab to platinum-based chemotherapy in recurrent or metastatic cervical cancer improves:
- A Pathological complete response rate only
- B Progression-free survival and overall survival ✓
- C Overall survival without benefit in progression-free survival
- D Disease-free survival in adjuvant setting after chemoradiation
Correct answer: B. Progression-free survival and overall survival
Explanation
GOG 240 (Tewari et al., NEJM 2014) demonstrated that adding bevacizumab (anti-VEGF monoclonal antibody) to cisplatin/paclitaxel or topotecan/paclitaxel chemotherapy significantly improved both overall survival (17 vs 13.3 months) and progression-free survival in recurrent, persistent, or metastatic cervical cancer. This made bevacizumab the first targeted agent to show overall survival benefit in cervical cancer. It is used in the palliative/recurrent setting, not as adjuvant therapy.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.